U.S. Incyte to Spend Up to $2 Billion to Expand Hematology Pipeline
On June 8, U.S. biopharmaceutical company Incyte announced it has reached a definitive agreement to ...
Chime Biologics Launches GMP-2 Facility in Wuhan, Plans AI-Driven Super Factory
Chime Biologics announced the official launch of its GMP-2 production facility in Wuhan, China. The ...
U.S. FDA Grants Regenerative Medicine Advanced Therapy Designation to lasme-cel
Cellectis announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medici...
US FDA Approves Eli Lilly's EBGLYSS Every-8-Week Maintenance Dosing Regimen
Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved a maintenanc...
Mayo Clinic Maps Over 500,000 Cells in Meningioma Atlas
Mayo Clinic, in collaboration with the Princess Margaret Cancer Centre in Toronto, published a study...
Brazil's Biomm expects ~3000% Ebitda growth by 2026
Brazilian pharmaceutical company Biomm (the only domestic producer of insulin glargine) has released...
Antengene's ATG-201 Receives IND Approval in China for the Treatment of Autoimmune Diseases
Antengene Corporation announced that the China National Medical Products Administration (NMPA) has a...
German Evotec Appoints Rui Wang as Global Head of Computational Science and Artificial Intelligence
Evotec SE announced the appointment of Rui Wang as Global Head of Computational Science and Artifici...
Brazil's Ávita Care seeks approval for semaglutide weight-loss pen within June
Ávita Care is accelerating the submission of final supplementary materials to Brazil's National Heal...
Zealand's Phase 2 Trial Shows 10.7% Weight Reduction
Zealand Pharma A/S (Zealand Pharma) announced new data from the Phase 2 ZUPREME-1 trial of its amyli...